Chongyang Huang, Huishi Tan, Jun Wang, Linwen Huang, Hongbin Liu, Yanqiang Shi, Cailing Zhong, Senhui Weng, Chunhui Chen, Wenyingzi Zhao, Zelong Lin, Jierui Li, Fachao Zhi, Beiping Zhang
Decreased levels of β-hydroxybutyrate (BHB), a lipid metabolic intermediate known to slow the progression of colorectal cancer (CRC), have been observed in the colon mucosa of patients with inflammatory bowel diseases (IBD). In particular, patients with recurrent IBD present an increased risk of developing colitis-associated colorectal cancer (CAC). The role and molecular mechanism of BHB in the inflammatory and carcinogenic process of CAC remains unclear. Here, the anti-tumor effect of BHB was investigated in the (Azoxymethane) AOM /(Dextran Sulfate Sodium) DSS-induced CAC model and tumor organoids derivatives...
May 8, 2024: Cancer Letters